Neuromodulation interventions in the management of heart failure

Amr Abdin1, Lucas Lauder1, Marat Fudim2,3

  • 1Internal Medicine Clinic III, Cardiology, Angiology and Intensive Care Medicine, Saarland University Hospital, Homburg, Germany.

PubMed

Insights

Heart failure (HF) management needs improvement, as many patients receive suboptimal treatment. Device-based neuromodulation offers a promising non-pharmacological approach to target autonomic imbalance and potentially improve HF outcomes.

Area of Science:

  • Cardiology
  • Neurology
  • Biomedical Engineering

Background:

  • Heart failure (HF) is a growing global health concern with significant healthcare costs.
  • Current HF management often involves suboptimal medication use, highlighting the need for novel therapeutic strategies.
  • Autonomic nervous system imbalance is a key factor contributing to HF progression.

Purpose of the Study:

  • To review the physiological basis of autonomic imbalance in heart failure.
  • To examine existing clinical data on non-pharmacological interventions for HF.
  • To explore the potential therapeutic role of device-based neuromodulation in managing heart failure.

Main Methods:

  • Literature review of physiological mechanisms in HF.
  • Analysis of clinical trial data on neuromodulation techniques.
  • Synthesis of evidence regarding device-based interventions for HF patients.

Main Results:

  • Autonomic dysfunction is prevalent and detrimental in heart failure.
  • Non-pharmacological approaches, including neuromodulation, show potential in HF management.
  • Device-based neuromodulation offers a novel avenue for addressing autonomic imbalance.

Conclusions:

  • Device-based neuromodulation represents a promising therapeutic frontier for heart failure.
  • Further research is warranted to optimize and validate these interventions.
  • Targeting autonomic imbalance may alleviate HF symptoms and improve patient prognosis.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
432
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
591
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
341
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
384
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Regulation of Heart Rates01:31

Regulation of Heart Rates

The regulation of heart rate is a complex process controlled by the autonomic nervous system (ANS), hormonal influences, and intrinsic cardiac mechanisms. The ANS has two main components: the sympathetic nervous system (SNS) and the parasympathetic nervous system (PNS).
The SNS increases heart rate through the release of norepinephrine and epinephrine, which act on beta-1 adrenergic receptors in the heart. This action increases the rate of depolarization in the sinoatrial (SA) node, the heart's...
1.8K